Some time ago, HIPRA took an important strategic decision: to develop and manufacture its own medical devices for the most correct administration of its vaccines. Coccidiosis in chickens is one of HIPRA’s strategic areas where it has recently launched a new and innovative coccidiosis vaccine, EVALON®. For this reason, the development of Hipraspray® was a natural consequence and is now a reality.
In terms of prevention against coccidiosis in chickens, Hipraspray® represents a turning point and a major leap forward in the use of vaccination devices.
With this system, HIPRA offers a high performance vaccination device specifically designed to ensure maximum efficacy of its EVALON® and Hipracox® products. In addition, HIPRA brings benefit to both the hatchery and the final producer.
HIPRA has enhanced its corporate strategy to overcome both current and future challenges. HIPRA is the first company to have digitised the animal health vaccination process, through Smart Vaccination.
In light of the desperate need for parameter optimisation in the livestock farming industry, HIPRA has emerged as the leader in the traceability of vaccination processes.
In this regard, HIPRA deems transparency from hatchery to the end producer to be vital, offering more information concerning the vaccination process against coccidiosis in chickens to all parties involved. This is ensured by software called HIPRAlink®, a platform for tracing, managing and analysing all the data coming from the vaccination process.
With HIPRAlink®, it is possible to trace information such as the doses administered, details of the vaccine batches, details regarding the operation and use of the Hipraspray® device, and to add more information that is of interest to the final producer about the batch of vaccinated chicks.
For a number of years, HIPRA has been strategically tackling the development and production of these devices, which are fully compatible with the characteristics of its products under development.
Biological products –and especially vaccines against coccidiosis in chickens- are extremely complicated to administer, which is why a fully coordinated and parallel approach to both vaccine and device production is vital in order to guarantee the best return on investment for the end customer.
This was achieved by introducing structural changes throughout the company and establishing new departments charged with meeting the needs of customers with highly technical and multidisciplinary requirements.
With a view to generating as much information as possible about the vaccination process and the products used, HIPRA opted to insert RFID chips into the vial labels. The coccidiosis in chickens line of vaccines –EVALON® and HIPRACOX®– was one of the first to carry these chips in the labels.
This has revolutionised the production process and the production lines in particular. This has been achieved thanks to the company’s flexibility, ability to rapidly adapt and the optimism with which it approaches new and exciting challenges.
Combining the worlds of biology, veterinary medicine, engineering and information technology is no easy task. In doing so, HIPRA has enhanced its corporate strategy to overcome both current and future challenges. HIPRA is the first company to have digitised the animal health vaccination process, through Smart Vaccination.
HIPRA’s future looks bright and is full of new challenges in such novel areas as traceability of livestock production processes, the Internet of Things (IoT), Big Data and decision-making, as well as artificial and predictive intelligence in diagnostics, while continuing to offer innovative and exclusive services to its customers.